Connect your AI

Ingevity NGVT Short-term restricted investments

Short-term restricted investments at other companies

UroGen PharmaURGN

$177K+0.6%

Intercontinental ExchangeICE

$884M+43.3%

UFP Industries, Inc.UFPI

$51.3M+22.0%

IngevityNGVT

$24.7M—

Construction PartnersROAD

$16.15M-20.1%

Intercontinental ExchangeICE

$70M+6.1%

Other financials

Income statement

Revenue$258.0M+4.1%

Gross profit$116.4M+4.0%

Net income$59.8M+192%

EPS (diluted)$1.66+196%

Balance sheet

Cash & equivalents$95.4M+5.0%

Total debt$1.4B-9.0%

Total equity$38.9M-83.4%

Total assets$1.7B-19.7%

Cash flow

Operating cash flow-$2.0M-108%

CapEx$10.3M+3.0%

Free cash flow-$12.3M-180%

Valuation

Market cap$2.53B+73.9%

Enterprise value$3.8B+32.4%

P/S2.1×+0.9×

Profitability

Gross margin39.3%+1.5pp

Net margin-10.6%-4.1pp

FCF margin20.3%+12.6pp

Returns & leverage

Return on equity-93.5%+1.2pp

Debt / equity35.1×+28.7×

Current ratio1.4×-0.6×

Where this comes from

Reported directly by Ingevity in its filing.

Tagged under the XBRL concept us-gaap:RestrictedInvestmentsCurrent.

The official record: Ingevity’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ingevity's short-term restricted investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Ingevity's short-term restricted investments?: Ingevity (NGVT) reported short-term restricted investments of $85.1M in Q1 2026.